| Document |
Document Title |
|
WO/2024/077264A3 |
The present disclosure provides methods for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a GPX4 inhibitor and a PARP inhibitor, wherein the subject is BRCA1 deficient (e.g., ...
|
|
WO/2024/108658A1 |
An immune-cell-membrane-coated gold nanocage material, and a preparation method therefor and the use thereof. The immune-cell-membrane-coated gold nanocage material is obtained by coating gold nanocage particles with cell membranes of im...
|
|
WO/2024/111626A1 |
The present invention provides a thiazole derivative that has an ALK5 inhibitory action and that is represented by formula (1) (refer to the description with respect to R1, R2, and Z in the formula), or a pharmaceutically acceptable salt...
|
|
WO/2024/112932A1 |
The invention provides compounds of formula I : and salts thereof, wherein R4, A, Z, Ra, and Rb have any of the values defined herein, and salts thereof. The compounds have immunomodulatory properties.
|
|
WO/2024/112853A1 |
Disclosed herein are compounds according to Formula I. (I). Compounds according to Formula I inhibit PKMYT1 and are useful for the treatment of cancer and other disease. The present invention also provides methods for making compounds as...
|
|
WO/2024/073525A3 |
The present disclosure provides methods for predicting prognosis of a cancer patient treated with a GD2/GD3 vaccine, including detecting the levels of anti-GD2-IgA and/or anti-GD2-IgG3 antibodies in the patient. Also disclosed herein are...
|
|
WO/2024/108614A1 |
A fusion gene containing an encoding gene of a chimeric antigen receptor and an encoding gene of a chimeric switch receptor and the use thereof. Specifically disclosed are a fusion protein having an amino acid sequence of SEQ ID NO. 1 an...
|
|
WO/2024/112480A1 |
Described herein are treatment regimens, therapies, pharmaceutical formulations and methods of using quercetin to prevent, treat, and/or protect from muscle wasting including 1) sarcopenia associated with aging; and 2) cachexia associate...
|
|
WO/2024/111657A1 |
In one embodiment of the present invention, it was discovered that a preparation containing an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region other than a hinge region can be mo...
|
|
WO/2024/109788A1 |
The present invention relates to a PARP7 inhibitor compound shown in formula I, a preparation method therefor, and a use thereof in treating and/or preventing PARP7-mediated diseases.
|
|
WO/2024/110956A1 |
Monoclonal antibodies that target human EMMPRIN and bind to a specific epitope are provided as well as compositions and uses in treating, diagnosing and staging diseases and disorders that involve pathologic angiogenesis, such as angioge...
|
|
WO/2024/109727A1 |
The present disclosure relates to a crystalline form of a pharmaceutically acceptable salt of a pyrazolo heteroaryl derivative. Specifically, the present disclosure relates to a crystalline form of a pharmaceutically acceptable salt of a...
|
|
WO/2024/110905A1 |
The present disclosure provides antibody drug conjugates comprising antibodies and antigen-binding fragments thereof that bind to human CEA and a linker-payload, a pharmaceutical composition comprising the anti-CEA antibody drug conjugat...
|
|
WO/2024/108568A1 |
Disclosed in the present invention are an anti-human leukocyte antigen-G nanobody, and a preparation method therefor and the use thereof. The anti-human leukocyte antigen-G nanobody has an amino acid sequence as shown in any one of SEQ I...
|
|
WO/2024/112717A1 |
The present invention provides a biologically active mRNA composition (e.g., an mRNA vaccine composition) for treating cancer and methods for using the same. In particular, the present invention relates to a biologically active mRNA comp...
|
|
WO/2024/112609A1 |
The invention relates to a gene expression based biomarker that is predictive of patient clinical need for treatment that includes a PD-1 antagonist, wherein the gene expression based biomarker comprises five or more genes selected from ...
|
|
WO/2024/108303A1 |
Lymphoid leukemia such as acute lymphoblastic leukemia (ALL) represents a devastating disease especially when it occurs in adults. While dose-intensification strategies have led to a significant improvement in outcomes for pediatric pati...
|
|
WO/2024/109936A1 |
The present disclosure relates to a quinoline amine compound crystal form and a preparation method therefor. Specifically, the present disclosure provides a crystal form of 8-chloro-N-(2,2-difluorobenzo[d][1,3]dioxolane-5-yl)quinolin
e-2...
|
|
WO/2024/110583A1 |
The invention relates to compounds and compositions that are useful as selective β2-adrenoceptor (β2-AR) antagonists and their use in the treatment and prevention of disease.
|
|
WO/2024/108268A1 |
The present invention relates to a method of treating cancer in a human subject who is non-responsive to treatment with an immune checkpoint inhibitor, to a method of reducing non- responsiveness of a subject to treatment with an immune ...
|
|
WO/2024/109918A1 |
A compound as represented by general formula (I) or a stereoisomer, a racemate, a deuterated substance, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or co-crystal thereof, an intermediate thereof, and a preparat...
|
|
WO/2024/112821A1 |
The present disclosure relates to expression of fusion proteins for cancer immunotherapy in a mammalian subject, such as a human subject. In particular, the present disclosure relates to mRNA, self-replicating RNA, and temperature-sensit...
|
|
WO/2024/105206A1 |
This application relates to antibody-drug conjugates cleavable in a tumor microenvironment by proteases such as neutrophil elastase, pharmaceutical compositions comprising the same, processes for preparation thereof, and the use thereof ...
|
|
WO/2024/106394A1 |
Provided is a technique for selectively recognizing triple negative breast cancer cells (TNBCs). An anti-TNBC antibody that selectively recognizes TNBCs compared to HER2-positive breast cancer cells and hormone receptor positive breast...
|
|
WO/2024/105180A1 |
The application generally relates to the treatment of cancer in patients who exhibit immune cells, in particular myeloid cells, for example Tumor Associated Macrophages, Monocytes, myeloid dendritic cells, MDSCs, and/or Tumor Associates ...
|
|
WO/2024/106876A1 |
The present invention relates to a pharmaceutical composition for inhibiting cancer metastasis and, preferably, to a pharmaceutical composition for inhibiting invasion or metastasis by invasive colon cancer. The composition of the presen...
|
|
WO/2024/107763A1 |
The present disclosure relates to proteolysis targeting chimeras (PROTACs) that modulate N6-adenosine-5 methyltransferase and methods of using the same.
|
|
WO/2024/104354A1 |
Provided are a crystal of a substituted piperazine derivative and a preparation method therefor. Specifically, provided are crystal forms A-I of a compound represented by formula (1) and a preparation method therefor.
|
|
WO/2024/103188A1 |
This invention provides compound having the structure of Formula I: (I) and uses of such compounds for modulating Lin28 activity, which may target an interaction site between the Lin28 ZKD and the Let‐7 GGAG motif and prevent Lin28 fro...
|
|
WO/2024/107759A2 |
The present invention provides antibodies that bind specifically to FGFR3 and methods for treating or preventing cancer, such as bladder cancer.
|
|
WO/2024/107494A1 |
The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods useful for treating patients having a HOXB13 genetic variant. In a specific embodiment, a method for identif...
|
|
WO/2024/104416A1 |
The present invention relates to an siRNA and an siRNA conjugate for inhibiting the expression of the sterol regulatory element binding protein cleavage activator protein (SCAP) gene, a pharmaceutical composition comprising same, and use...
|
|
WO/2024/107765A2 |
The present invention provides, in part, protein-drug conjugates comprising an anti-fibroblast growth factor receptor 3 (FGFR3) (e.g., human FGFR3) antigen-binding protein (e.g., scFv, Fab) conjugated to a molecular cargo (e.g., polynucl...
|
|
WO/2024/106914A1 |
The present invention relates to heteroayl derivatives and uses thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against EGFR and/or HER2, which may be usefully employed as a therapeutic ...
|
|
WO/2024/107895A1 |
Provided are methods and dosage regimens for treating cancer using an antibody that specifically binds to human DDR1 and an immune checkpoint inhibitor.
|
|
WO/2024/106941A1 |
The present invention relates to: an expression cassette comprising a polynucleotide that encodes a chimeric antigen receptor effective in cancer treatment; and an effector cell into which the expression cassette is transduced. Particula...
|
|
WO/2024/105197A1 |
The present invention relates to novel pharmaceutical compounds comprising one or more binding molecules (e.g., target protein binders, T) capable of binding to target proteins expressed on tumor cells or on cells present in the tumor mi...
|
|
WO/2024/104425A1 |
The present invention pertains to the technical field of pharmaceuticals and particularly relates to a KRAS inhibitor compound, a pharmaceutical composition thereof, and use thereof. Specifically, the present invention relates to a compo...
|
|
WO/2024/104475A1 |
Disclosed in the present invention are cyclic compounds used as multi-target kinase inhibitors and a preparation method therefor. The multi-target kinase inhibitors of the present invention are represented by general formula I, wherein R...
|
|
WO/2024/107393A1 |
The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and ph...
|
|
WO/2024/107859A1 |
Substituted cyclopentene-oxymethylene phosphonamidates and related compounds, pharmaceutical compositions, their use for inhibiting LINE1 reverse transcriptase and/or HERV- K reverse transcriptase activity, and their use in the treatment...
|
|
WO/2024/105147A1 |
The present specification relates methods of treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic or loco-regionally recurrent breast cancer, comprising administering a next ...
|
|
WO/2024/108131A1 |
The disclosure herein provides compounds and pharmaceutical compositions of Formula (I), (II), (III), (IV), (V), or (VI) for killing cancer cell or inhibiting cancer cell proliferation. Further, the compounds and pharmaceutical compositi...
|
|
WO/2024/104304A1 |
Provided in the present invention are a compound as represented by formula (I) and a prodrug thereof, which have a good inhibitory effect on MDM2 and/or MDMX, and can be used for treating MDM2- and/or MDMX-mediated conditions and/or dise...
|
|
WO/2024/108100A1 |
The present application provides heteroaryl fluoroalkene compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
|
|
WO/2024/106866A1 |
The present invention relates to a DNA construct including: a gene encoding a flagellin protein; and a gene encoding an immunoenhancer (adjuvant) protein. For effective cancer therapy by selectively killing only cancer cells, an attenuat...
|
|
WO/2024/107955A1 |
Disclosed herein is a method of treating breast cancer by administering 8-cyclopentyl- 2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydr
opyrido[2,3-d]pyrimidine-6-carbonitrile, alone or in combination with a second agent such...
|
|
WO/2024/107996A1 |
The present disclosure provides pharmaceutical combinations comprising MetAP2 inhibitors for the treatment of prostate cancer.
|
|
WO/2024/107041A1 |
The invention relates to medicine, and more particularly to oncology, and can be used for treating malignant diseases by the administration of sodium nucleinate in combination with chemoradiotherapy. The method provides an improvement in...
|
|
WO/2024/107959A1 |
Described herein are minimal virus-like particles (mVLPs), comprising a membrane comprising a phospholipid bilayer with one or more ectodomain-truncated VSV envelope glycoproteins on the external side; and a biomolecule cargo disposed in...
|
